A Phase 2 interventional study of Bone Marrow Aspiration and Biopsy and Carfilzomib in ISS Stage III Plasma Cell Myeloma and Multiple Myeloma, sponsored by Mayo Clinic. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 96th largest by enrollment, is one of 5 that started in 2022, is one of 50 in phase 2, reaches primary completion later than 10 of the 38 other live ones, and was the 100th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 6 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
84 studies in Multiple Myeloma by Mayo Clinic: 11 open now, 16 under way, 1 of them phase 3. Of 65 finished, 41 (63%) have results posted.
Among the 84 studies in Multiple Myeloma by Mayo Clinic, this one is the 53rd largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2022, is one of 35 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 70th registered.
Mayo Clinic’s Multiple Myeloma studies by the year they started, since 1993.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Mayo Clinic’s 84 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.
PRIMARY OBJECTIVE:
I. To estimate the rate of sustained minimal residual disease (MRD) negativity (MRD negative status at any point, with a repeated MRD negative status one year later) in subjects with high-risk multiple myeloma.
SECONDARY OBJECTIVES:
I. To describe the toxicities associated with this treatment approach in subjects with high-risk multiple myeloma (MM).
II. To estimate the overall response rate, very good partial response (VGPR) or better rate and complete response (CR) rate at the end of induction, end of consolidation, end of maintenance and at two years after the completion of treatment.
III. To estimate the progression-free survival and overall survival rate.
CORRELATIVE RESEARCH OBJECTIVES:
I. To describe the clonal architecture through a combination of genomic, epigenomic, proteomic and metabolomic studies before and after treatment, in subjects with high-risk MM.
II. To describe the bone marrow microenvironment through various stages of treatment and the time of MRD negative state and at time of relapse.
OUTLINE:
INDUCTION: Patients receive carfilzomib intravenously (IV) on days 1, 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide orally (PO) days 1-21 of each cycle, daratumumab subcutaneously (SC) days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo bone marrow aspirate and biopsy, blood sample collection, echocardiography (ECHO) or multigated acquisition (MUGA) scan, and magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET)/CT throughout the study. Patients also undergo chest radiography (x-ray) during screening.
After completion of study treatment, patients are followed up every 6 months for up to 10 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to take aspirin (325 mg) daily as prophylactic anticoagulation.
High risk myeloma, which is untreated, defined as any two of:
Exclusion Criteria:
Diagnosed or treated for another =\< 1 year prior to pre- registration or previously diagnosed with another malignancy and have any evidence of residual disease.
Other concurrent chemotherapy, or any ancillary therapy considered . NOTE: Concurrent chemotherapy is any treatment not related to multiple myeloma.
If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INDUCTION: Patients receive carfilzomib IV on days 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide PO days 1-21 of each cycle, daratumumab SC days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy, MRI and, CT/PET.
Procedure: Bone Marrow Aspiration and Biopsy · Drug: Carfilzomib · Procedure: Computed Tomography · Biological: Daratumumab · Drug: Dexamethasone · Drug: Lenalidomide · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Procedure: Multigated Acquisition Scan · Procedure: Biospecimen Collection · Procedure: Echocardiography · Procedure: Chest Radiography
Undergo bone marrow aspiration and biopsy
Given IV
Also known as: Kyprolis, PR-171
Undergo CT or PET/CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography
Given SC
Also known as: Darzalex, HuMax-CD38, JNJ-54767414, Daratumumab Biosimilar HLX15, Daratumumab-fihj
Given IV/PO
Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex
Given PO
Also known as: CC-5013, CC5013, CDC 501, Revlimid
Undergo MRI
Also known as: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging
Undergo PET/CT
Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Undergo MUGA scan
Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo ECHO
Also known as: EC
Undergo chest x-ray
Also known as: chest x-ray
Rate of Sustained Minimal Residual Disease (MRD) Negativity
MRD negative status at any point, with a repeated MRD negative status one year later. All subjects meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable, with the exception of subjects determined to be a major violation. The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, \>\>\> 2016) was used for response assessment.
Time frame: 1 year
Overall Response Rate
The overall response rate will be defined as the percentage of patients that achieved confirmed very good partial response (VGPR) or better by The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, 2016) at the designated timepoint.
Time frame: At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment)
Overall Survival
Defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.
Time frame: 3 years
Progression-Free Survival
Defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
Time frame: 3 years
Incidence of Adverse Events
Adverse Events: All eligible subjects that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each subject, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the trial treatment will be taken into consideration. AEs will be summarized overall, as well as by treatment phase (induction, consolidation, maintenance with carfilzomib and lenalidomide and daratumumab). The percent of patients with a grade 3 or higher event will be reported for both the Induction and Consolidation timepoints.
Time frame: Monthly up to 3 years after start of induction treatment
Clonal Architecture Before Treatment
To determine the clonal architecture before treatment, after treatment in subjects with residual disease and in subjects who have disease progression after attaining MRD negativity.
Time frame: Before and after treatment, up to two years or 24 months
Bone Marrow Microenvironment
To evaluate the bone marrow microenvironment before and after treatment and the time of MRD negative state.
Time frame: Before and after treatment, up to two years or 24 months
| Milestone | Treatment (Combination Chemotherapy) |
|---|---|
| Started | 17 |
| Completed | 5 |
| Not completed | 12 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Ineligible | 1 |
| Withdrew: Alternative treatment | 1 |
| Withdrew: Physician decision | 7 |
| Milestone | Treatment (Combination Chemotherapy) |
|---|---|
| Started | 5 |
| Completed | 0 |
| Not completed | 5 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Premature study closure | 2 |
| Milestone | Treatment (Combination Chemotherapy) |
|---|---|
| Started | 0 |
| Completed | 0 |
| Not completed | 0 |
MRD negative status at any point, with a repeated MRD negative status one year later. All subjects meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable, with the exception of subjects determined to be a major violation. The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, \>\>\> 2016) was used for response assessment.
| percentage of patients | Treatment (Combination Chemotherapy) |
|---|---|
| Rate of Sustained Minimal Residual Disease (MRD) Negativity | 11.8 |
The overall response rate will be defined as the percentage of patients that achieved confirmed very good partial response (VGPR) or better by The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, 2016) at the designated timepoint.
| percentage of patients | Treatment (Combination Chemotherapy) |
|---|---|
| At end of induction | 76.5 |
| At end of consolidation | 17.7 |
Defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.
| months | Treatment (Combination Chemotherapy) |
|---|---|
| Overall Survival | NA (NA to NA) |
Defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
| Months | Treatment (Combination Chemotherapy) |
|---|---|
| Progression-Free Survival | 22 (14.9 to NA) |
Adverse Events: All eligible subjects that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each subject, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the trial treatment will be taken into consideration. AEs will be summarized overall, as well as by treatment phase (induction, consolidation, maintenance with carfilzomib and lenalidomide and daratumumab). The percent of patients with a grade 3 or higher event will be reported for both the Induction and Consolidation timepoints.
| percentage of patients | Treatment (Combination Chemotherapy) |
|---|---|
| Induction | 88.2 |
| Consolidation | 40 |
To determine the clonal architecture before treatment, after treatment in subjects with residual disease and in subjects who have disease progression after attaining MRD negativity.
Results for this outcome have not been posted.
To evaluate the bone marrow microenvironment before and after treatment and the time of MRD negative state.
Results for this outcome have not been posted.
Collected over Adverse events were followed for 2 years. Mortality was followed for 3 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Treatment (Combination Chemotherapy) | 0/17 (0%) | 2/17 (11.8%) | 17/17 (100%) |
| Consolidation Treatment (Combination Chemotherapy) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Event | Induction Treatment (Combination Chemotherapy) | Consolidation Treatment (Combination Chemotherapy) |
|---|---|---|
| Ventricular tachycardiaCardiac disorders | 0/17 | 1/5 |
| Prostate infectionInfections and infestations | 0/17 | 1/5 |
| Heart failureCardiac disorders | 1/17 | 0/5 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/17 | 0/5 |
| Thromboembolic eventVascular disorders | 1/17 | 0/5 |
| Event | Induction Treatment (Combination Chemotherapy) | Consolidation Treatment (Combination Chemotherapy) |
|---|---|---|
| FatigueGeneral disorders | 7/17 | 5/5 |
| Lymphocyte count decreasedInvestigations | 16/17 | 5/5 |
| AnemiaBlood and lymphatic system disorders | 9/17 | 4/5 |
| Alanine aminotransferase increasedInvestigations | 2/17 | 4/5 |
| Alkaline phosphatase increasedInvestigations | 6/17 | 4/5 |
| Neutrophil count decreasedInvestigations | 7/17 | 4/5 |
| Platelet count decreasedInvestigations | 9/17 | 4/5 |
| White blood cell decreasedInvestigations | 9/17 | 4/5 |
| DiarrheaGastrointestinal disorders | 4/17 | 3/5 |
| Back painMusculoskeletal and connective tissue disorders | 4/17 | 3/5 |
| Age, Continuous(years) | Treatment (Combination Chemotherapy) |
|---|---|
| Mean | 61.47 ± 9.1 |
| Sex: Female, Male(Participants) | Treatment (Combination Chemotherapy) |
|---|---|
| Female | 7 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Treatment (Combination Chemotherapy) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Treatment (Combination Chemotherapy) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in Feb 2026, 40 months.
Results were first posted in Nov 2026, 8 months after primary completion.
Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's 40 months is below that.
Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carfilzomib · Daratumumab · Dexamethasone · Lenalidomide